These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38839200)

  • 1. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men.
    Johannesen CDL; Langsted A; Nordestgaard BG; Mortensen MB
    J Am Coll Cardiol; 2024 Jun; 83(23):2262-2273. PubMed ID: 38839200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.
    Doi T; Langsted A; Nordestgaard BG
    Atherosclerosis; 2024 Jun; 393():117556. PubMed ID: 38678642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
    Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
    Eur Heart J; 2024 Jul; 45(27):2410-2418. PubMed ID: 38700053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
    Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
    Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
    JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins.
    Balling M; Afzal S; Varbo A; Langsted A; Davey Smith G; Nordestgaard BG
    J Am Coll Cardiol; 2020 Dec; 76(23):2725-2735. PubMed ID: 33272366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.
    Quispe R; Martin SS; Michos ED; Lamba I; Blumenthal RS; Saeed A; Lima J; Puri R; Nomura S; Tsai M; Wilkins J; Ballantyne CM; Nicholls S; Jones SR; Elshazly MB
    Eur Heart J; 2021 Nov; 42(42):4324-4332. PubMed ID: 34293083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study.
    Wadström BN; Pedersen KM; Wulff AB; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1144-1155. PubMed ID: 38511326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
    JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study.
    Yun SY; Rim JH; Kang H; Lee SG; Lim JB
    Ann Lab Med; 2023 May; 43(3):237-243. PubMed ID: 36544335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
    JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
    Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
    Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
    Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
    J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
    Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
    JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
    Sniderman AD; Islam S; McQueen M; Pencina M; Furberg CD; Thanassoulis G; Yusuf S
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27737874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.